EUCTR2020-004612-97-LT进行中（未招募）1 期
A phase IIb, double-blind, randomised, placebo-controlled trial to evaluate the efficacy and tolerability of ZED1227 in celiac disease subjects experiencing symptoms despite gluten-free diet
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Signed informed consent,
- •Men or women between 18 and 80 years of age, inclusively,
- •Documented initial biopsy proven diagnosis of celiac disease or, in case of missing histological documentation, TG2-IgA > 10 x upper limit of normal (ULN) at diagnosis at least 12 months prior to V0
- •Adherence to a gluten-free diet (GFD) for at least 12 months prior to V0
- •Human leukocyte antigen DQ (HLA-DQ) typing compatible with celiac disease
- •At least one moderate or severe gastrointestinal symptom (i.e., diarrhoea, abdominal pain, bloating or nausea) during the last 4 weeks prior to Baseline Visit, Visit 2, and Baseline Visit B
- •Negative diagnosis of Helicobacter pylori infection
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 330
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 70
排除标准
- •Presence of hypo- or hyperthyroidism
- •Subjects diagnosed to have confirmed refractory celiac disease type I (RCDI) or II (RCDII), with the exception that patients with a diagnosis of RCDI can be considered for inclusion if they do not have clear signs of T cell monoclonality or atypical T cells and if they do not present with very severe symptoms and/or parameters of significant malabsorption and if they have not received prior treatment with immunosuppressants such as budesonide or azathioprine,
- •Severe complications of celiac disease [e.g., enteropathy associated T-cell lymphoma (EATL), ulcerative jejunitis, perforation],
- •Concomitant diseases of the intestinal tract in addition to celiac disease that might, in the investigator's opinion, interfere with assessment of symptoms of abdominal pain, diarrhoea, or other components of celiac disease,
- •Evidence of relevant systemic disease
研究者
相似试验
进行中（未招募）
1 期
A clinical trial to evaluate ZED1227 in comparison with placebo in subjects with celiac disease experiencing symptoms despite gluten-free dietTreatment of celiac diseaseMedDRA version: 20.0Level: LLTClassification code 10007864Term: Celiac diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2020-004612-97-DEDr. Falk Pharma GmbH400
招募中
1 期
A clinical trial to evaluate ZED1227 in comparison with placebo in subjects with celiac disease experiencing symptoms despite gluten-free dietEUCTR2020-004612-97-IEDr. Falk Pharma GmbH400
招募中
1 期
A clinical trial to evaluate ZED1227 in comparison with placebo in subjects with celiac disease experiencing symptoms despite gluten-free dietEUCTR2020-004612-97-PLDr. Falk Pharma GmbH400
进行中（未招募）
1 期
A clinical trial to evaluate ZED1227 in comparison with placebo in subjects with celiac disease experiencing symptoms despite gluten-free dietTreatment of celiac diseaseMedDRA version: 20.0Level: LLTClassification code 10007864Term: Celiac diseaseSystem Organ Class: 100000004856EUCTR2020-004612-97-EEDr. Falk Pharma GmbH400
招募中
1 期
A clinical trial to evaluate ZED1227 in comparison with placebo in subjects with celiac disease experiencing symptoms despite gluten-free dietEUCTR2020-004612-97-ATDr. Falk Pharma GmbH400